Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...
The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...
After getting a metastatic breast cancer diagnosis, you may experience anxiety and depression. Here are some ways to manage ...
When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...
The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...
To further refine risk stratification, other mental health conditions or diagnostic tools should be considered, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback